<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 03 Jun 2021 07:50:25 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>2020全球新药研发回顾</title><link>https://mp.weixin.qq.com/s/7jFaiizZG1UYqUD_NQnNEA</link><description></description><content:encoded><![CDATA[2020全球新药研发回顾]]></content:encoded><pubDate>Thu, 03 Jun 2021 06:18:10 +0800</pubDate></item><item><title>CAR-T治疗中的细胞因子释放综合征与相关神经毒性</title><link>https://mp.weixin.qq.com/s/ca6KlNUOQjxC_n-2DV5w6w</link><description></description><content:encoded><![CDATA[CAR-T治疗中的细胞因子释放综合征与相关神经毒性]]></content:encoded><pubDate>Wed, 02 Jun 2021 07:20:07 +0800</pubDate></item><item><title>新药论坛三箭齐发，吐槽大会爆笑江湖｜BiG年会DAY 2</title><link>https://mp.weixin.qq.com/s/fzvAiPl0WIQZAbmBLtVNXw</link><description></description><content:encoded><![CDATA[新药论坛三箭齐发，吐槽大会爆笑江湖｜BiG年会DAY 2]]></content:encoded><pubDate>Wed, 02 Jun 2021 07:20:07 +0800</pubDate></item><item><title>双特异性抗体的发展历程！</title><link>https://mp.weixin.qq.com/s/UkHdxlBocWvDeI9DDh8hdA</link><description></description><content:encoded><![CDATA[双特异性抗体的发展历程！]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>SIRPa抗体单药实体瘤安全有效，力压CD47，大有可为</title><link>https://mp.weixin.qq.com/s/TN2n3ztWW5cPuAtTyNC-lg</link><description></description><content:encoded><![CDATA[SIRPa抗体单药实体瘤安全有效，力压CD47，大有可为]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>双抗、ADC新玩家入局，5月融资企业“挑战”龙头地位</title><link>https://mp.weixin.qq.com/s/zZvc-mKf3q7drRPEUWvmVA</link><description></description><content:encoded><![CDATA[双抗、ADC新玩家入局，5月融资企业“挑战”龙头地位]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>免疫学拾遗-第14章：B细胞的发育</title><link>https://mp.weixin.qq.com/s/s5Ya54K5a0KcbJWPmL3Vpg</link><description></description><content:encoded><![CDATA[免疫学拾遗-第14章：B细胞的发育]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>免疫学拾遗-第15章：T细胞的发育</title><link>https://mp.weixin.qq.com/s/Y-R8jhdVUoR_gZQZ4NTkCw</link><description></description><content:encoded><![CDATA[免疫学拾遗-第15章：T细胞的发育]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>张文宏领衔燃BiG，八位研发掌门人再决BB-King之巅｜年会盛况</title><link>https://mp.weixin.qq.com/s/Mmw3NhDGQg-bVJcKEo5J5w</link><description></description><content:encoded><![CDATA[张文宏领衔燃BiG，八位研发掌门人再决BB-King之巅｜年会盛况]]></content:encoded><pubDate>Mon, 31 May 2021 06:52:46 +0800</pubDate></item><item><title>IL7融合蛋白临床疗效初现</title><link>https://mp.weixin.qq.com/s/P8yNccGdy_SNNkKGVvDUGA</link><description></description><content:encoded><![CDATA[IL7融合蛋白临床疗效初现]]></content:encoded><pubDate>Sun, 30 May 2021 06:22:28 +0800</pubDate></item><item><title>盘点2021上市的抗体新药-（4）amivantamab-vmjw</title><link>https://mp.weixin.qq.com/s/nP8q8iWAJSXAC2L2SwxLmQ</link><description></description><content:encoded><![CDATA[盘点2021上市的抗体新药-（4）amivantamab-vmjw]]></content:encoded><pubDate>Sun, 30 May 2021 06:22:28 +0800</pubDate></item><item><title>重磅！FDA加速批准AMG510上市，KRAS-“不可成药”靶点的逆袭之路</title><link>https://mp.weixin.qq.com/s/4FAhtzkS_EFdIZVFmDpdLA</link><description></description><content:encoded><![CDATA[重磅！FDA加速批准AMG510上市，KRAS-“不可成药”靶点的逆袭之路]]></content:encoded><pubDate>Sat, 29 May 2021 07:20:49 +0800</pubDate></item><item><title>百亿补体抑制剂市场江湖风云再起</title><link>https://mp.weixin.qq.com/s/loZzObsbd4sr_STABD8K-w</link><description></description><content:encoded><![CDATA[百亿补体抑制剂市场江湖风云再起]]></content:encoded><pubDate>Fri, 28 May 2021 06:12:25 +0800</pubDate></item><item><title>FDA发布双特异性抗体研发指南</title><link>https://mp.weixin.qq.com/s/nJmbi1F12f7kpHGMq_t3HA</link><description></description><content:encoded><![CDATA[FDA发布双特异性抗体研发指南]]></content:encoded><pubDate>Thu, 27 May 2021 06:29:48 +0800</pubDate></item><item><title>中国生物药研发现状与未来</title><link>https://mp.weixin.qq.com/s/utqalrdRLVgYMDQpg2Tk-w</link><description></description><content:encoded><![CDATA[中国生物药研发现状与未来]]></content:encoded><pubDate>Wed, 26 May 2021 06:32:42 +0800</pubDate></item><item><title>2020细胞免疫疗法研究报告</title><link>https://mp.weixin.qq.com/s/UVPmOHnzOOuALdsCnfEw2A</link><description></description><content:encoded><![CDATA[2020细胞免疫疗法研究报告]]></content:encoded><pubDate>Tue, 25 May 2021 06:20:07 +0800</pubDate></item></channel></rss>